Kryxana 200mg Tablet

Kryxana 200mg Tablet contains ribociclib 200mg, a prescription CDK4/6 inhibitor used as targeted therapy for adults with hormone receptor-positive (HR+), HER2-negative breast cancer. Ribociclib is marketed as Kryxana in several markets and as Kisqali® in others. It is used in combination with endocrine therapy for eligible patients with early, locally advanced, or metastatic breast cancer according to the applicable regulatory indication.

The 200mg tablet is an important strength of ribociclib and can form part of the prescribed daily dose or be used for dose modification when clinically indicated. In the U.S., the approved regimen for HR+/HER2− early breast cancer is 400mg once daily (two 200mg tablets) for 21 days followed by 7 days off, while advanced or metastatic disease generally uses 600mg once daily (three 200mg tablets) for 21 days followed by 7 days off.

Kryxana should be prescribed and monitored by a healthcare professional experienced in cancer treatment.

Product Information

Brand Name

Kryxana®

Generic Name

Ribociclib

Active Ingredient

Ribociclib

Strength

200mg

Dosage Form

Film-Coated Tablet

Drug Class

Cyclin-Dependent Kinase 4/6 (CDK4/6) Inhibitor

Therapeutic Class

Targeted Anticancer Therapy

Route

Oral

Primary Indication

HR-positive, HER2-negative breast cancer

Uses

Early, locally advanced, or metastatic breast cancer according to applicable approval

Combination Therapy

Aromatase inhibitor or fulvestrant, depending on indication

Prescription

Yes

Manufacturer/Brand

Novartis / market dependent

Tablet Strength

200mg ribociclib per tablet

What Is Kryxana 200mg Tablet?

Kryxana 200mg is an oral targeted cancer medicine containing ribociclib.

Ribociclib belongs to the CDK4/6 inhibitor class. These medicines interfere with proteins called cyclin-dependent kinases 4 and 6, which are involved in regulating progression through the cell cycle.

By inhibiting CDK4/6 activity, ribociclib can help slow the proliferation of certain breast cancer cells. It is particularly used in tumors that are hormone receptor-positive and HER2-negative.

Kryxana 200mg for Breast Cancer

Kryxana is primarily associated with treatment of HR-positive, HER2-negative breast cancer.

For advanced or metastatic disease, ribociclib is combined with endocrine therapy such as an aromatase inhibitor or fulvestrant depending on the clinical situation. In early breast cancer, ribociclib can be used with an aromatase inhibitor for eligible patients at increased risk of recurrence.

This creates the primary commercial search relationship:

Kryxana 200mg → Ribociclib 200mg → CDK4/6 Inhibitor → HR+/HER2− Breast Cancer → Targeted Breast Cancer Treatment

Kryxana 200mg and Kisqali®

Kryxana® and Kisqali® contain the same active ingredient, ribociclib, but the brand name used can differ by market.

Kisqali is the Novartis brand name used in the United States and several other markets, while Kryxana is used in markets including parts of Asia. The exact product authorization, packaging and approved indications should always be checked for the relevant country.

Where an appropriately authorized equivalent or generic product is available, relevant commercial searches may include Ribociclib 200mg, Generic Ribociclib 200mg, Generic Kryxana 200mg, Generic Kisqali 200mg and Ribociclib 200mg Tablet.

Kryxana 200mg Monitoring

Treatment with ribociclib requires appropriate oncology monitoring.

Depending on the treatment setting, healthcare professionals may monitor:

• Complete blood counts
• Liver function
• Electrolytes
• ECG/QT interval
• Signs and symptoms of lung toxicity
• Treatment response and tolerability

Ribociclib also has clinically important drug-interaction considerations, including interactions involving CYP3A inhibitors and inducers.

Availability & Ordering

Kryxana 200mg Tablet is a prescription oncology medicine. Customers searching for Kryxana 200mg, Kryxana 200mg Tablet, Ribociclib 200mg, Buy Kryxana 200mg, Buy Ribociclib 200mg, Kryxana 200mg Price, Ribociclib 200mg Price, Generic Kryxana 200mg, Generic Kisqali 200mg and related transactional terms should obtain the medicine through an appropriately licensed pharmacy or authorized pharmaceutical supplier.

Availability, prescription requirements, approved indications, import regulations and dispensing requirements vary across the USA, UK, UAE/Dubai, Australia, Singapore, Thailand, China and Russia.

How it works

Ribociclib selectively inhibits CDK4 and CDK6.

These enzymes normally help regulate the transition of cells from the G1 phase into the S phase of the cell cycle. Inhibition of CDK4/6 can prevent susceptible cancer cells from progressing through the cell cycle and multiplying.

This mechanism makes ribociclib a targeted cell-cycle therapy rather than a conventional cytotoxic chemotherapy.

Kryxana/ribociclib is used for eligible patients with HR-positive, HER2-negative breast cancer.

Depending on the applicable regulatory approval, uses include:

• HR+/HER2− early breast cancer at high risk of recurrence, as adjuvant treatment with an aromatase inhibitor
• HR+/HER2− locally advanced or metastatic breast cancer in combination with an aromatase inhibitor
• HR+/HER2− advanced or metastatic breast cancer in combination with fulvestrant in appropriate patients

In pre- or perimenopausal patients, endocrine therapy may also require ovarian suppression with an LHRH agonist. Approved indications and treatment requirements vary by market.

The prescribed ribociclib dose depends on the indication, treatment combination, patient characteristics and tolerability.

For example, current U.S. prescribing information specifies:

• Early breast cancer: 400mg once daily, equivalent to two 200mg tablets, for 21 consecutive days followed by 7 days off.
• Advanced or metastatic breast cancer: 600mg once daily, equivalent to three 200mg tablets, for 21 consecutive days followed by 7 days off.

Dose interruptions or reductions may be required because of adverse reactions or other clinical factors. The 200mg tablet may therefore be used as part of the prescribed dose or for dose modification.

Do not change the dosage or treatment schedule without instructions from the treating oncologist.

Ribociclib can cause adverse effects and requires medical monitoring.

Potential adverse reactions include:

• Neutropenia and other blood-cell abnormalities
• Nausea
• Fatigue
• Diarrhea
• Headache
• Vomiting
• Alopecia
• Liver-function abnormalities
• Infections

Important serious risks include QT interval prolongation, hepatotoxicity and interstitial lung disease/pneumonitis. Patients should report symptoms such as fainting, abnormal heartbeat, breathing difficulties, persistent cough, fever or other concerning symptoms promptly to their healthcare provider.